Ambrosia Biosciences Raises $100M to Develop Small-Molecule GLP-1 Pills That Could Replace Injections

Ambrosia Biosciences, a Boulder, Colorado-based drug discovery company, has closed an oversubscribed $100 million Series B financing round to advance its pipeline of oral small-molecule GLP-1 receptor agonists — a potential next-generation alternative to the injectable peptide drugs that currently dominate the obesity treatment market. The round was co-led by Blue Owl Healthcare Opportunities, Redmile, and Deep Track Capital.

GLP-1 receptor agonists, a class of drugs that mimic the glucagon-like peptide-1 hormone to regulate appetite and blood sugar, have become the fastest-growing drug category in pharmaceutical history. Semaglutide, a GLP-1 receptor agonist marketed as Ozempic and Wegovy by Novo Nordisk, and tirzepatide, a dual GIP/GLP-1 receptor agonist sold as Mounjaro and Zepbound by Eli Lilly, generated tens of billions in combined revenue in 2025. But both require regular injections, a barrier that limits patient uptake.

The small-molecule advantage

Ambrosia's approach differs fundamentally from current GLP-1 therapies. Rather than engineering peptide chains — short proteins that must be injected because the gut would break them down — the company uses cryo-electron microscopy and AI-powered drug design to create small chemical compounds that activate the GLP-1 receptor orally. The team includes former scientists from Array BioPharma, the Colorado company acquired by Pfizer in 2019 for $11.4 billion.

"The current generation of GLP-1 drugs has proven the biology works," the company stated in its announcement. "The question now is whether we can deliver the same efficacy in a more accessible form."

A crowded but lucrative race

Ambrosia is not alone in pursuing oral small-molecule GLP-1 drugs. Structure Therapeutics recently reported positive Phase 2 data for aleniglipron, its once-daily oral GLP-1 pill. Pfizer, which stumbled with its earlier oral GLP-1 candidate danuglipron, is also reportedly retooling its approach. Eli Lilly's orforglipron, a non-peptide oral GLP-1 agonist, is in Phase 3 trials.

The global GLP-1 market, valued at approximately $22.5 billion in 2023, is projected to exceed $196 billion by 2032 — giving even late entrants reason to invest heavily. Ambrosia's broader pipeline also includes candidates targeting GIP and glucagon receptors for combination cardiometabolic therapies.

The Phase 1 trial of Ambrosia's lead candidate is expected to begin later in 2026.